Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile

Why is Walmart CEO Doug McMillon retiring? How did AI aid Chinese hacking campaigns? What caused the recent tech stock selloff? Why are US tariffs on Swiss goods being cut? How will Meta’s AI impact employee evaluations work? What’s behind rising US mortgage foreclosures? Why is Bitcoin falling to six-month lows?

Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile

benzinga.com/news/health-care/25/11/48786533/neurocrines-depression-drug-fails-phase-2-goal-but-shows-encouraging-safety-profile

On Monday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) said its Phase 2 study of NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint compared to placebo, though it was generally well tolerated.
Neurocrine Biosciences acquired the rights to develop and…

This story appeared on benzinga.com, 2025-11-11 17:51:54.